Literature DB >> 3159974

Alzheimer's disease in Down's syndrome: clinicopathologic studies.

K E Wisniewski, A J Dalton, C McLachlan, G Y Wen, H M Wisniewski.   

Abstract

Clinical and neuropathologic evidence points to the development of Alzheimer's disease (AD) in seven Down's syndrome patients above age 40. Dementia was observed in these patients over periods of 2.5 to 9.2 years. The first clinical sign of AD, visual memory loss, was succeeded by impaired learning capacity and decreased occupational and social functioning, and culminated in seizures and urinary incontinence. The morphometric observations of the brains of these seven patients with AD showed that the numbers of plaques and tangles exceeded 20 per 1.5 X 10(6) microns2 area, in both the prefrontal and hippocampal cortices. Plaques and tangles were also evident in the basal ganglia, thalamus, hypothalamus, and midbrain. In addition, we found that four of the seven brains showed small strokes, and five of the seven amyloid angiopathy. This study also indicates that by longitudinal neuropsychological evaluations and lab tests, which exclude other causes of dementia, the diagnosis of AD can be made even in severely and profoundly retarded patients.

Entities:  

Mesh:

Year:  1985        PMID: 3159974     DOI: 10.1212/wnl.35.7.957

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  105 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

2.  Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease.

Authors:  M A Pappolla; R A Omar; K S Kim; N K Robakis
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

3.  Differential expression of PARP1 mRNA in leucocytes of patients with Down's syndrome.

Authors:  Michele Salemi; Concetta Barone; Carmelo Romano; Federico Ridolfo; Eleonora Gulotta; Cataldo Scavuzzo; Maria Grazia Salluzzo; Mariaconcetta Giambirtone; Filippo Caraci; Corrado Romano; Paolo Bosco
Journal:  J Genet       Date:  2011-12       Impact factor: 1.166

4.  Expression of LDOC1 mRNA in leucocytes of patients with Down's syndrome.

Authors:  Michele Salemi; Concetta Barone; Carmelo Romano; Federico Ridolfo; Roberto Salluzzo; Francesco Scillato; Cataldo Scavuzzo; Filippo Caraci; Aldo E Calogero; Corrado Romano; Paolo Bosco
Journal:  J Genet       Date:  2012       Impact factor: 1.166

5.  Working memory in the aged Ts65Dn mouse, a model for Down syndrome.

Authors:  Katharine N Whitney; Galen R Wenger
Journal:  Behav Brain Res       Date:  2012-04-04       Impact factor: 3.332

Review 6.  Understanding protein non-folding.

Authors:  Vladimir N Uversky; A Keith Dunker
Journal:  Biochim Biophys Acta       Date:  2010-02-01

7.  Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome.

Authors:  Jisook Moon; May Chen; Shruti U Gandhy; Myla Strawderman; David A Levitsky; Kenneth N Maclean; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

8.  Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome.

Authors:  Brian E Powers; Ramon Velazquez; Christy M Kelley; Jessica A Ash; Myla S Strawderman; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Brain Struct Funct       Date:  2015-12-30       Impact factor: 3.270

9.  Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain.

Authors:  J Motte; R S Williams
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

10.  CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  Hippocampus       Date:  2018-02-12       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.